Suboxone, medically known as Buprenorphine, is used to help ease symptoms of opiate addiction. However, by itself, it can be used to provide pain relief for chronic pain. Since it helps patients who suffer from opiate addiction, those who use the drug can inevitably find themselves addicted to the substance. This is where the help and assistance of a suboxone withdrawal facility in Florida will prove helpful.
Factors that affect withdrawal
Once a person has decided to undertake withdrawal and recovery, there are several things that must be considered. If the person is still using suboxone to deal with his opiate addiction, then the withdrawal process will not work, the Mental Health Daily cautions. That’s because the person will still need to be exposed to the drug to counter his opiate addiction, rendering any move toward withdrawal useless. Withdrawal symptoms depend on the length of time the person has been addicted to the drug. Also, before deciding to go through with this process, one must be prepared to go through the withdrawal symptoms.
How long does it last?
The more far along the addiction and drug dependency is, the longer the withdrawal will take. Drugs change the composition of the body. Those who have taken it for months will typically find it easy to come off the addiction, compared to those who have been taking the drug for years. Those who come out of their opiate addiction using the substance also find it difficult to come off Suboxone.
Does physiology matter?
Withdrawal symptoms differ from one person to another. Some might find themselves dealing with slews of painful symptoms while others might only experience mild ones. Your physiology and nervous system will influence the length of the withdrawal process. For instance, someone who’s fit and healthy will have a less difficult time with the withdrawal than someone who’s unhealthy, depressed or stressed.
Can you stop taking it immediately?
It is unsafe for anyone to stop taking the drug without first consulting with their doctors. The wisest course of action is to get in touch with a suboxone withdrawal facility in Florida to help one through the withdrawal process. Medical supervision and monitoring will help alleviate the symptoms and keep the body safe from succumbing to the more severe forms of symptoms that might occur, such as heart attacks or seizures.
By getting professional help, users are well able to get a better chance at recovery and a drug-free life.
NEW YORK, NY – March 22, 2017 /Press Release/ ––
Heroin use is associated with excessive histone acetylation, an epigenetic process that regulates gene expression, and more years of drug use correlate with higher levels of hyperacetylation, according to research conducted at The Icahn School of Medicine at Mount Sinai and published April 1 in the journal Biological Psychiatry. The study provides the first direct evidence of opiate-related epigenetic alterations in the human brain, indicating that the drug alters accessibility to portions of DNA to be either open or closed, thereby controlling whether genes implicated in addiction are switched on or off.
The Mount Sinai study focuses on epigenetics, the study of changes in the action of human genes caused, not by changes in DNA code we inherit from our parents, but instead by molecules that regulate when, where, and to what degree our genetic material is turned on and off. Histone acetylation of DNA-linked proteins is an essential process for gene regulation by which an acetyl functional group is transferred from one molecule to another, thereby activating gene expression.
To uncover the molecular underpinnings of heroin addiction, the Mount Sinai study team focused on the striatum, a brain region implicated in drug addiction because of its central role in habit formation and goal-directed behavior. Studying postmortem human tissue from 48 heroin users and 37 controls, they found acetylation changes at genes that regulate the function of glutamate, a neurotransmitter that regulates the drug reward system and controls drug-seeking behavior. Specifically, changes were identified at the glutamate receptor gene GRIA1, which has previously been implicated in drug use.
“We hypothesized that the epigenetic impairments uncovered in our study reflect changes that would increase accessibility to DNA that is required to enhance gene transcription that subsequently plays an important role in addiction behavior,” says Yasmin Hurd, PhD, Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai and Director of The Center for Addictive Disorders at the Mount Sinai Behavioral Health System, who led the study. “Because epigenetic impairments are physical alterations to the DNA that do not change the sequence of a gene, they have the potential to be reversed, so our next step was to address this possibility.”
Using a rat model of heroin addiction, researchers allowed rats to self-administer heroin and observed the same hyperacetylation alterations that were found in the postmortem human brains. The study team then treated the heroin-addicted rats with JQ1, a compound originally developed against cancer pathology, which inhibits the readout of acetylated epigenetic proteins thereby reducing accessibility to the DNA that was previously induced by heroin. The drug reduced heroin self-administration among study rats. Importantly, JQ1 also reduced drug-seeking behavior after abstinence from heroin, suggesting it might be beneficial for long-term heroin users.
“Our findings suggest that JQ1 and similar compounds might be promising therapeutic tools for heroin use disorder,” says Dr. Hurd. “Furthermore, the animal model we created that displayed analogous epigenetic impairments related to heroin use will be useful for future studies looking to identify addiction-related changes that translate to the human brain.”
Researchers from Semmelweis University in Budapest, Hungary, contributed to this study.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.
The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in “Best Children’s Hospitals.”
For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Source: The Mount Sinai Hospital